Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Lixte Biotechnology Holdings Inc
LIXT
Healthcare
Biotechnology
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint...
blockers and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series consists of novel structures, which treat not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which has the potential to be effective in its class and may be useful for the treatment of chronic hereditary diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:LIXT)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 17, 2023 12:15pm
LIXT....On watch post RS 2 x's
Early a.m runner then PB No position unfortunately ; )
(135)
•••
Walter333
X
View Profile
View Bullboard History
Post by
Walter333
on Jun 16, 2023 9:33pm
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
[url=https://https://clinicaltrials.gov/ct2/show/NCT03027388]clinical trial [/url]
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 12, 2022 4:03pm
LIXT .... I'm only going to say this once.....
Don't be "that guy" who chases sh8t like this !!!!
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 12, 2022 2:18pm
LIXT ..... Here is a lesson..... NR was at 10:53 p.s.t.
The share price meltdown was instantaneously after the announcement ...just sayin https://invst.ly/xwqcl
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 12, 2022 2:10pm
LIXT ..... good reason to move the share price up and .....
bury all the chasers ; ) I call the finacing a "curveball" It's all about raising money .....leaving the shareholders with the high priced paper They Shorted this P.O..... all the
...more
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 12, 2022 2:06pm
LIXT ..... Suckers are born every minute !!!
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market 2022-04-12 10:53 ET - News Release PASADENA, CA, April 12, 2022 (GLOBE
...more
(30)
•••
MushLove
X
View Profile
View Bullboard History
Comment by
MushLove
on Jan 05, 2022 11:31pm
RE:LIXT....toast?
You are done, like a side b!tch with hella drama, bounce like a basketball!
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 05, 2022 10:24am
LIXT....toast?
Early a.m runner ....NR Volume & price action Gallant effort....but she is done.... JMHO
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
Do you want to stay ahead of the markets? See how DealRoom can help.